Jon Congleton, Chief Executive Officer of Mineralys Therapeutics, Inc. (NASDAQ: MLYS), has executed a significant transaction involving the company's equity. On July 13, 2026, Congleton sold 10,700 shares of Mineralys common stock. The aggregate value of this divestment reached $291,441. The transaction was facilitated through prices ranging from $26.80 to $27.58 per share, resulting in a weighted-average sale price of $27.2375.
This sale was executed pursuant to a Rule 10b5-1 trading plan that Mr. Congleton adopted on January 28, 2025. The implementation of such a plan typically indicates a pre-determined schedule for trading, designed to comply with securities regulations regarding insider trading. Following this specific transaction, Mr. Congleton's direct ownership stake in Mineralys Therapeutics stands at 603,621 shares of common stock.
Mineralys Therapeutics has recently been engaged in substantial capital raising activities. The company announced the pricing of a public stock offering, which is expected to generate approximately $150 million in proceeds. This offering consists of 5,660,378 shares priced at $26.50 per share. The transaction is anticipated to close shortly, contingent upon the satisfaction of customary conditions. Furthermore, Mineralys has secured a total of $750 million through various financial transactions. These funds are directed toward repurchasing royalty obligations and strengthening the company's balance sheet. A key component of this financial restructuring involves a $200 million upfront payment to Tanabe Pharma Corporation, with an additional potential of up to $100 million upon the achievement of specific milestones. In exchange, Tanabe has assigned its intellectual property rights for the drug lorundrostat to Mineralys.
The market context surrounding this executive sale shows Mineralys stock trading at $27.33. This price point represents a 5.7% decline over the past week. However, the stock has demonstrated a strong 90.7% return over the past year. Analyst opinions on the biopharma company remain divided. Jefferies has reiterated a Hold rating on Mineralys, maintaining a $30 price target. The firm notes the potential for an acquisition during the FDA review of the company's new drug application. In contrast, H.C. Wainwright has maintained a Buy rating with a $56 price target. This bullish view highlights recent post hoc analysis from the pivotal Launch-HTN trial, which was presented at a European conference. This analysis focused on lorundrostat, a treatment for uncontrolled or resistant hypertension. Mineralys also presented clinical data from the same trial, revealing that among participants with chronic kidney disease, 71% were on multiple anti-hypertensive medications. This data emphasizes the potential impact of lorundrostat in a complex patient population.
According to InvestingPro analysis, the stock appears overvalued at current levels. Investors seeking deeper insights can access 9 additional ProTips and comprehensive Pro Research Reports covering MLYS and 1,400+ other US equities on the platform.